14Nov 2023
Concomitant Proton Pump Inhibitor Use Associated with Adverse Outcomes in Small Cell Lung Cancer Immunotherapy

Concomitant Proton Pump Inhibitor Use Associated with Adverse Outcomes in Small Cell Lung Cancer Immunotherapy

In the realm of advanced small cell lung cancer (SCLC) treatment, programmed death-ligand 1 (PD-L1) inhibitors have gained prominence as a primary therapeutic avenue. The study, conducted between July 2018 and February 2021, scrutinized data from 208 SCLC patients undergoing PD-L1 inhibitor therapy to explore the influence of concomitant proton pump inhibitor (PPI) use on treatment outcomes. The results revealed a noteworthy disparity in progression-free survival (PFS) and overall survival (OS) between patients receiving PPIs and those without. Specifically, PPI use correlated with a 74.9% elevated risk of progression and a 58.3% increased risk of death, indicating a detrimental impact on clinical outcomes. This finding underscores the need for careful consideration of concomitant medications in immunotherapy regimens for SCLC.

  • #pulmonology

Like

Save

Share